secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001628280-25-008873
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025
--------------------------------------------------------------------------------

- Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.
- Cash, equivalents, and investments $204.5M at Dec 31, 2024, up from $135.2M.
- Initial clinical data from PM359 Phase 1/2 for p47 phox CGD expected in 2025.
- IND/CTA filing for PM577 (Wilson's Disease) planned for first half of 2026.
- Cash runway expected into first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/0001628280-25-008873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/prme-20250228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer